Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced...

SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the...

SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US, Europe and Israel SoniVie, which has developed a novel proprietary...

SoniVie, an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive disorders, announced that on January 8th 2024, the last patient was...

The funds, provided by new investors and current shareholder, will be used to support the Company clinical and regulatory path towards pre-market approval of its TIVUS™ technology for the treatment...

TEL AVIV, Israel, July 13, 2022 /PRNewswire/ — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS™) System to treat a variety of hypertensive disorders, announced that...

TEL AVIV, Israel, June 20, 2022 /PRNewswire/ — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound System (TIVUS™) to treat a variety of hypertensive disorders, announced that...

SoniVie announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the TIVUS System for renal artery denervation for the treatment of...

SoniVie today announced that it has received FDA approval for its IDE for a pivotal study of the Therapeutic Intra-Vascular Ultrasound (TIVUS) System in patients with pulmonary arterial hypertension (PAH)....